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Abstract 
Ovarian cancer is known as a serious malignancy that affects women’s reproductive tract and can considerably threat 
their health. A wide range of molecular mechanisms and genetic modifications have been involved in ovarian cancer 
pathogenesis making it difficult to develop effective therapeutic platforms. Hence, discovery and developing new 
therapeutic approaches are required. Medicinal plants, as a new source of drugs, could potentially be used alone or in 
combination with other medicines in the treatment of various cancers such as ovarian cancer. Among various natural 
compounds, quercetin has shown great anti-cancer and anti-inflammatory properties. In vitro and in vivo experi-
ments have revealed that quercetin possesses a cytotoxic impact on ovarian cancer cells. Despite obtaining good 
results both in vitro and in vivo, few clinical studies have assessed the anti-cancer effects of quercetin particularly in 
the ovarian cancer. Therefore, it seems that further clinical studies may introduce quercetin as therapeutic agent alone 
or in combination with other chemotherapy drugs to the clinical setting. Here, we not only summarize the anti-cancer 
effects of quercetin but also highlight the therapeutic effects of quercetin in the ovarian cancer.
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Introduction
According to a 2018 report, ovarian cancer ranked as the 
seventh most prevalent female cancer across the world, 
with approximately 240,000 new subjects [1]. Ovarian 
cancer usually is diagnosed in advanced stages, since 
it is associated with silent and unclear symptoms [2]. 
Despite extensive knowledge obtained on this complica-
tion in recent years, the rate of survival has not improved 
significantly because of some challenges in diagnosing 
and treatment it as early as possible [3]. Different modifi-
cations in molecular and genetic levels in ovarian cancer 
result in some challenges to establish a therapeutic plat-
form [4].
According to a wide range of experiments, phyto-
chemicals including polyphenols, flavones, as well as fla-
vonoids possess considerable anti-cancer features, which 
can be employed against different kinds of cancers [5]. In 
this regard, quercetin, which can be extensively observed 
in daily foods including nuts, teas, vegetables, different 
plants, and in general the daily dietary program of peo-
ple, is a common phytochemical [6]. Moreover, this sup-
plementary agent is commercially accessible, while its 
oral application at a dose of 1  g per day is safe enough 
and can be absorbed up to 60% [7]. An extensive range 
of pharmacologic activities has been reported for querce-
tin, including anti-oxidant, anti-diabetes, anti-inflam-
mation, as well as anti-proliferation [8, 9]. Quercetin, 
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2-(3,4-dihy-droxyphenyl)-3,5,7-trihydroxy4H-chromen-
4-one includes two benzene rings named A and B, and 
joined through a 3-carbone heterocyclic pyrone one [9]. 
Since two antioxidant pharmacophores are present in the 
structure of quercetin, it can largely remove free radicals 
and join to transitional metal ions [9]. Moreover, cat-
echol along with the OH group presenting at the position 
C3 in the structure of quercetin is an ideal arrangement 
to scavenge free radicals [9]. This agent is a pental-
hydroxyl-flavonol consisting of 5 hydroxyl groups on the 
flavonol structure at 3, 30, 40 5, and 7 position carbons. 
Replacement of various functional groups leads to differ-
ent biochemical as well as pharmacologic properties of 
quercetin [10].
Some studies have indicated that quercetin may exist 
in two states: (i) free or aglycone and (ii) mixed with dif-
ferent molecules. It can be interacted with molecules 
including, carbohydrates, lipids, alcohols, as well as sul-
fate group to generate derivatives of quercetin such as 
quercetin glycoside, prenylated quercetin, quercetin 
ethers and quercetin sulfate [10].
Furthermore, significant number of studies focused on 
anti-cancer properties of this bioactive compound. Sev-
eral pathways have been identified which are affected by 
quercetin in different cancers [11, 12]. Based on available 
evidences, quercetin can inhibit a broad range of cancers 
such as breast [13], lung [14], nasopharyngeal [15], kid-
ney [16], colorectal [17], prostate [18], pancreatic [19], as 
well as ovarian [20] cancers. According to the previous 
literature, consuming vegetables that are rich in querce-
tin has been associated with lower risks of ovarian can-
cer [21]. Similarly, consuming fruits with high levels of 
quercetin, including apples as well as citrus or their juice 
can decrease occurrence of ovarian cancer [22].
Quercetin is not harmful for healthy cells, while it can 
impose cytotoxic effects on cancer cells through several 
mechanisms, making it a good candidate to treat ovarian 
cancer or to be employed as a supplementary factor along 
with other anti-cancer medications [23]. In this review, 
we summarized the recent and eminent researches on 
quercetin properties in cancer therapy, especially ovarian 
cancer.
Quercetin and its biologic functions
Quercetin is an ordinary flavonoid that is perva-
sive in various types of foods and plant. Quercetin 
glycosides are the dominant flavonoid content that 
can be found in propolis along with other healthy 
foods, including fruits and vegetables; particu-
larly onion, broccoli, apple, tea, as well as red wine. 
International Union of Pure and Applied Chemis-
try (IUPAC) has called it 3,3′,4′,5,7-pentahydroxy-
flavone (Fig.  1). Another name for this agent is 
3,3′,4′,5,7-pentahydroxy-2-phenylchromen-4-one, and 
five hydroxyl groups are present at the positions 3, 5, 
7, 3′ and 4′ of the flavonoid as its typical characteristic 
[24–26]. Quercetin can be used as a nutritional supple-
ment. Quercetin is reported to have several beneficial 
effects on human health such as anti-inflammatory 
effects, cardiovascular protection and anticancer activ-
ity. It can act as an anti-cancer, anti-tumor, anti-ulcer, 
anti-allergy, anti-viral, anti-inflammation, and anti-
diabetes agent, exerting gastro-protection, anti-hyper-
tension, immune-modulation, as well as anti-infection 
features are among its advantageous effects [27].
Ferry and colleagues have investigated the pharma-
cokinetic effects of intravenously injected quercetin 
in the patients with cancer at doses of 60–2000  mg/
m2. The safe dose of 945  mg/m2 was identified by the 
researchers. At higher doses that were toxic, vomit-
ing, high blood pressure, nephrotoxicity, as well as 
decreased serum potassium could be observed. The 
dispensation and removal half-life of quercetin applied 
intravenously, is 0.7–7.8  min, and 3.8–86  min, cor-
respondingly. Elimination is 0.84  L/min/m2, and dis-
pensation content is 3.7  L/m2 [28]. Pharmacokinetic 
characteristics of oral administration of 8, 20, and 
500  mg quercetin aglycone were examined in healthy 
volunteers by Erlund et  al. [29]. On the other hand, 
Graefe and colleagues examined the pharmacoki-
netic features of this agent at a dose of 200  mg.  Cmax 
as well as  Tmax of quercetin have been reported to be 
2.3 ± 1.5 µg/mL and 0.7 ± 0.3 h, correspondingly [30].
Angiogenesis is one of very important cancer-related 
processes. It has been showed, quercetin exerts its anti-
angiogenesis effects in various cancers (Fig.  2) [31]. 
Moreover, quercetin is capable to protect against free 
radicals including smoking. Free radicals originated 
from cigarette tar can impose irreparable damages to 
erythrocyte membranes. In addition, quercetin and its 
Fig. 1 Chemical structure of quercetin (Q1)
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conjugate metabolites have been reported to possess 
the potential to protect erythrocytes against damage of 
the membrane resulted from smoking [32].
Inflammation, through which self-protecting measures 
are taken, is a type of biologic reaction in the case human 
body experiences damaging or troublesome stimuli. 
The aim of this process is removing of the injured cells, 
pathogens, or other adverse stimuli, while beginning the 
treatment procedure. Inflammatory conditions are not 
essentially equal to infection. Infection is usually resulted 
from a viral, bacterial, or fungal source, but inflammatory 
processes include the reaction of the human body toward 
healing itself [33, 34]. The potential of quercetin in mod-
ulation of inflammation is one of its critical and consid-
erable features. Accordingly, inflammatory enzymes of 
cyclooxygenase (COX) and lipoxygenase are inhibited 
by this agent and consequently inflammatory media-
tors including prostaglandins as well as leukotrienes are 
reduced [33, 34].
Nutritionists at Michigan State University stud-
ied the general effects of dietary flavonoids includ-
ing quercetin as systemic anti-inflammation elements 
[35]. Increased level of C-reactive protein (CRP) was 
related to several disease conditions consisting of being 
obese, experiencing heart problems, as well as lupus. 
The researchers concluded that consumption of spe-
cific foods lowers the levels of inflammation risk factors 
(CRP).
Pre-clinical investigations have shown that querce-
tin can significantly reduce the levels of inflammation 
moderators including NO synthase, COX-2, as well as 
CRP in human hepatocyte-derived cell line [36]. Regard-
ing experiments carried out on rats, quercetin (80  mg 
equivalent dose) hindered acute and chronic inflamma-
tory conditions, while it also indicated considerable anti-
arthritic properties against adjuvant-induced arthritis 
[37, 38].
In a study performed by Askari and colleagues, the 
impact of 2-month flavonoid quercetin (500 mg) supple-
ment was examined in healthy amateur sportsmen hav-
ing regular exercise. The results of this study indicated a 
considerable reduction in CRP levels [39]. Nevertheless, 
in pathologic conditions, this agent did not cause consid-
erable changes in CRP levels in women who had rheu-
matoid arthritis (RA). The study continued in an 8-week 
interval, and the RA patients received 500  mg/day of 
quercetin [40]. Moreover, quercetin hampers the accu-
mulation of uric acid due to its capability of inhibiting 
Fig. 2 Anti-angiogenesis effects of quercetin
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xanthine oxidase, which is probably beneficial in patients 
suffering gout [41].
Quercetin has also antibacterial potential regarding 
approximately all kinds of bacteria, and especially influ-
ences gastrointestinal, respiratory, urinary, as well as 
dermal systems. Its anti-infection and anti-replication 
properties are probably due to its antiviral features. 
Viruses that usually react to flavonoids include adenovi-
rus, herpes simplex virus, Japanese encephalitis virus, as 
well as respiratory syncytial virus [42, 43].
Quercetin possesses anti-allergic properties through 
inhibition of releasing histamine from mast cells along 
with other allergic substances; therefore, it plays the role 
of a natural antihistamine. The potential of quercetin in 
prevention of allergies results in significant implications 
to employ it to treat and prevent asthma and bronchi-
tis. The cell membranes of mast cells have the role of an 
immune gateway for the brain, the environment, as well 
as emotional stress [44].
Although a broad range of biologic advantages was 
mentioned above, quercetin pharmaceutical application 
and clinical conditions have been constrained due to its 
low hydro-solubility, lack of stability in physiologic con-
ditions along with low bioavailability. [45]. It is worth 
considering that the anticancer properties of quercetin 
may be dependent to some extent on its metabolites [46–
48]. Currently, several analogs having better solubility 
and possessing various biologic features such as biphasic, 
inotropic and lusitropic impacts have been introduced 
[49, 50].
A review described the anticancer properties of a small 
collection of quercetin analogs, while the hydrophilic-
free OH have been completely or partially covered with 
groups that are conveniently removed considering in vivo 
conditions. Particularly, hydroxyl groups of the natural 
compound were replaced with different combinations, 
including acetyl esters, ethyl or benzyl ethers, or diphe-
nyl ketal of the catechol system. Alterations made in 
the chemicals resulted in compounds that had better 
anti-cancer properties regarding quercetin. In addition, 
the potential of the proposed analogs in inhibition of 
human topoisomerases I and II was examined through 
direct enzymatic assays along with docking analyses [51]. 
Eventually, findings regarding the capability of lead com-
pounds in modulation of intracellular ROS generations 
could be recorded.
The effect of quercetin on cancers
Despite many advances in treating cancer, it is still known 
as a life-threatening malignancy in human. Although 
chemotherapy is employed as the conventional treat-
ment for cancer, it has been illustrated that its usage is 
restricted in most cancers because of reasons including 
chemotherapy resistance and side effects.
Nowadays, natural compounds such as quercetin have 
been recognized as significant agent for preventing and 
healing cancer because of their predictable performance, 
high therapeutic potential and their low toxicity. It seems 
that quercetin plays an important role as an anti-prolif-
erative and anticancer agent and also stimulates apopto-
sis (Fig. 3) [52]. Numerous studies probed the influence 
of isolated quercetin compound in different cancer cell 
lines. Obviously, quercetin has repressed the proliferation 
of cancers such as gastric cancer (GC) [53], breast cancer 
[54], colorectal cancer (CRC) [55], oral cancer [56], liver 
cancer [57], prostate cancer [58], thyroid cancer [59], leu-
kemia [60], pancreatic cancer [61] and lung cancer [62].
Quercetin and gastrointestinal cancers
Gastrointestinal cancers, the leading causes of cancer-
related mortality worldwide, account for one fourth 
of all malignancies and for 9% of all cancer deaths [63], 
have elevating rate of incidence and heavy health bur-
den on society [64]. Quercetin significantly suppressed 
GC cell viability, migration and invasion activities via 
decreasing expression of urokinase plasminogen acti-
vator (uPA) and uPA receptor (uPAR) proteins, which 
are strongly associated with GC metastasis. Quercetin 
could be used as an anti-metastatic agent against GC 
metastasis cells through interfering with uPA/uPAR sys-
tems, AMPKα, NF-κβ, ERK1/2, and PKC-δ regulation 
[65]. Recently, quercetin was carried with a novel phe-
nyl boronic acid (PBA) conjugated ZnO nanoparticles 
(PBA-ZnO-Q) construct. It was determined that PBA-
ZnO-Q can be efficient in diminishing tumor growth, 
in vivo. KRAS is a mutant oncogenic gene in up to 40% 
of CRC patient that has been confirmed leads to resist-
ant chemotherapy and poor prognosis in CRC cases [17, 
66, 67]. Investigation of quercetin effects on CRC cells 
carrying KRAS mutant gene revealed that quercetin 
could decrease the cell viability and increase apoptosis 
in cancer cells based on MTT assay and colony forma-
tion methods. The possible underlying mechanisms are 
the AKT pathway repression and activation of the c-Jun 
N-terminal kinase (JNK) pathway in KRAS-mutant cells. 
[17]. Gold nanoparticles (AuNPs)-quercetin into poly dl-
lactide-co-glycolide nanoparticles significantly repressed 
the cell proliferation, colony formation, progression and 
cell migration of liver cancer. According to data, this con-
struct containing quercetin increased the apoptosis via 
enhancing of caspase-3, caspase-9, and provoked more 
freeing of cytochrome c (cyto-c). Quercetin nanopar-
ticle also repressed Akt/ERK1/2 signaling pathway, tel-
omerase reverse transcriptase (hTERT) via impending 
AP-2β/hTERT, and cyclooxygenase 2(COX-2) through 
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inactivated the NF-κB/COX-2. [68]. Treating HSC-6 and 
SCC-9 cell lies, oral cancer originated cell lines, with 
50 µM of quercetin showed inhibited cell viability, migra-
tion, and invasion via attenuated the excesses of MMP-9 
and MMP-2 in those cells. Beside, quercetin treatment 
alleviated the miR-16 expression, which were upregu-
lated in oral cancer cell line and tissues.
Quercetin and hematological cancers
Hematological cancers are diseases of abnormal pro-
genitor and stem cells, originating from epigenetic and 
genetic alterations that lead to the dysregulation of dif-
ferentiation, proliferation, and self-renewal of cells [69]. 
In the majority of these malignancies, the bone mar-
row, along with peripheral blood, lymphatic nodes, and 
spleen, as secondary lymphoid organs, are main loca-
tions for tumour localisation [70]. Quercetin has been 
also proved to possess beneficial effects on hematological 
cancers. He and his co-workers carried out an investiga-
tion and showed that quercetin inhibits proliferation of 
MM.1R, ARP-1, and RPMI8226 multiple myeloma cell 
lines through inducing apoptosis as well as cell cycle 
arrest in the G2/M phase. Moreover, the combination of 
quercetin with dexamethasone further enhanced apop-
tosis and inhibited tumor growth [71]. In another study, 
Ma et al. reported that quercetin inhibits multiple mye-
loma cells proliferation via down-regulating the expres-
sion of IQGAP1 and ERK activation [72]. It has been 
indicated that quercetin suppresses STAT3 and PI3K/
AKT/mTOR pathways in primary effusion lymphoma 
(PEL) cells leading to downregulate the prosurvival cel-
lular proteins expression, including cMyc, cyclin D1, and 
c-FLIP. Furthermore, quercetin decreased the IL-6 and 
IL-10 release, resulting in PEL cell death. A prosurvival 
autophagy was also mediated by quercetin, which pro-
moted the cytotoxic effects of bortezomib, a proteaso-
mal inhibitor [73]. Ha and colleagues demonstrated that 
quercetin induced cytoprotective autophagy and intrinsic 
apoptosis, and the suppression of autophagy with chloro-
quine potentiates apoptotic ability of quercetin in human 
T cell acute lymphoblastic leukemia Jurkat clones [74]. 
According to former studies, it was clarified TNF-related 
Fig. 3 A schema of the effects of quercetin on apoptosis
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apoptosis-inducing ligand (TRAIL) as a biological 
cytokine playing important role in promoting apoptosis 
through attaching to its agonist receptors in cancer cells 
but its utilization has been limited because of resist-
ance to some cancers [75, 76]. For this reason, a group 
of scientists has explored the synergist effect of quercetin 
and TRAIL in human myeloid leukemia KG-1 cells and 
showed that quercetin can be employed as a sensitizing 
factor alongside with TRAIL promoted the influence of 
TRAIL-induced apoptosis in KG-1 cells. On the basis of 
quantitative Real-time PCR results, it was observed the 
expression level of death receptor (DR) genes includ-
ing DR4 and DR5 after treating with quercetin were 
increased and also the p65 expression and antiapop-
totic proteins including c-IAP1, c-IAP2, and XIAP were 
reduced [75].
Quercetin and gynecological cancers
Gynecologic malignancies are the fourth most preva-
lent type of cancers in females and influence the organs 
and tissue of the reproductive system of women, such as 
the vulva-vagina, cervix, uterus, and ovaries [77–79]. To 
prove the effectiveness of quercetin for the treatment of 
gynecological malignancies, numerous researches have 
been performed. For example, Lin et  al. revealed that 
quercetin, by declining the expression of UBE2S, which is 
highly expressed in malignant cancers contributed to cell 
motility via epithelial–mesenchymal transition signaling, 
inhibits the invasion of cervical cancer cells [80].
Other cancers
Tummala et  al. showed that quercetin downregulated 
AR-V7 and hnRNPA1 expression, antagonized andro-
gen receptor signaling, and promoted the sensitization 
of enzalutamide-resistant prostate cancer cells to enza-
lutamide treatment [81]. In the case of melanoma ther-
apy, it was recently stated that quercetin inhibited the 
viability of A375SM melanoma cells through apoptosis 
induction. Additionally, it reduced the tumor volume 
in vivo and decreased the proliferation of cancerous cells 
in vitro [82]. Moreover, quercetin is a potent anticancer 
agent for the treatment of brain tumors, such as glio-
blastoma multiforme, as reviewed by Tavana et el. [83]. 
In human papillary thyroid cancer cell line (B-CPAP) 
quercetin significantly decreased cell proliferation and 
promoted apoptosis through caspase activation. It also 
provoked cell apoptosis through Hsp90 expression that 
may be associated with the reduction of chymotrypsin-
like proteasome activity. The elimination of chymot-
rypsin-like proteasome activity represses growth and led 
to cell death in thyroid cancer cells [59]. Since low bio-
availability of quercetin, Quagliariello et  al. were used a 
hyaluronic acid (HA) hydrogel as a carrier of quercetin 
and have explored the result of drug treatment alone or 
in combination to SNS-314 that is an anti-Aurora kinase 
in human medullary and papillary thyroid cancer cells. 
It was noted that HA acted as a ligand of CD44 which is 
sufficiently increased in various cancer cells and related 
to tumor progression [84, 85]. On the other hand, incor-
poration of quercetin and SNS-314 caused a synergistic 
cytotoxic influence on both cell lines with an important 
reduction of the IC50 value [85]. Wiśniewska and col-
leagues have demonstrated the impact of quercetin on the 
essential cytoskeletal elements, such as microfilaments, 
microtubules, cytoskeleton-driven processes and vimen-
tin intermediate filaments in A549 non-small cell lung 
cancer cells. Their results revealed that quercetin induced 
apoptosis via the regulation of BCL2/BAX, also necrosis 
and mitotic catastrophe, and repressed the migratory of 
those cells. The disassembling influence of quercetin on 
vimentin filaments, microtubules, and microfilaments 
accompanied by its suppression effect on N-cadherin and 
vimentin expression might be responsible for the reduced 
migration of A549 cells in reply to quercetin therapy. It 
is also reported that the probable mechanism underly-
ing quercetin -induced mitotic disaster comprise the dis-
turbance of mitotic microtubules results in monopolar 
spindle development, and subsequently the collapse of 
cytokinesis. They also proposed that quercetin can lead 
to the destruction of actin filaments leading to cytokine-
sis failure [86].
After 72 h treatment with 40 µM quercetin, decreased 
cell viability and promoted apoptosis follow by necro-
sis was reported in prostate cancer (Pca) cells treated 
compare to untreated ones. In addition, quercetin has 
impressing effects on the mitochondrial integrity and 
also depending on oxidation situation of the cells, can 
serve as an antioxidant or as a pro-oxidant for balancing 
reactive oxygen species (ROS) production in PCa cells. 
According to this study, quercetin repressed PCa via alle-
viating cell survival, frustrating anti-apoptotic pathways 
and also participate in MAPK, Akt, and NF-κB signaling 
pathways in different PCa cell lines with p53 mutated or 
without p53 mutated. Collectively, this research declared 
quercetin via regulation of ROS, Akt, and NF-κB path-
ways show an anti-cancer effect and could be utilized as a 
chemotherapeutic medicine to promote clinical results of 
PCa cases [87].
Nwaeburu et al. have surveyed the profiling of miRNA 
expression in AsPC1 (Pancreatic cancer cell line) cells 
before and after treatment with quercetin and indicated 
quercetin induced miR-200b-3p expression. This miRNA 
has a significant role in the choice of a Pancreatic Ductal 
Adenocarcinoma (PDA) cell to offer either symmetric or 
asymmetric division through regulating Notch signal-
ing [88]. Symmetric division causes two equal daughter 
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cells and leads to exponential tumor growth but asym-
metric cell division produce two different daughter cells 
and is presented through cancer stem cells(CSCs) for 
homeostasis [89–91]. Also, it was proved that miR-200b 
expressed highly in the normal pancreas cell and of 
course down-regulated in PDA cells [88, 92]. After treat-
ment of PDA cell with quercetin, the expression level of 
miR-200 was modulated which resulting to cell fate con-
trol and repression of cancer initiation, proliferation, 
invasion [88, 93, 94]. Table 1 listed various studies on the 
anti-cancer effects of quercetin.
Quercetin as novel therapy for ovarian cancer
Ovarian cancer is one of the most prevalent types of 
women malignancies and is responsible for the most 
deaths among the gynecologic cancers. In this cancer, 
there are some of the risk factors such as age, family 
history, late menopause, and null parity whiles with the 
pregnancy and breastfeeding reduce the occurrence risk 
[95].
The biology of ovarian cancer differs from that of 
hematogenously metastasizing tumors because ovarian 
cancer cells primarily disseminate within the peritoneal 
cavity and are only superficially invasive. Nevertheless, 
since the rapidly proliferating tumors compress visceral 
organs and are only temporarily chemosensitive, ovar-
ian carcinoma is a deadly disease [96] Ovarian cancers 
are separated into type I (low grade) and II (high-grade 
serous and carcinosarcoma) [97].
In the quest to produce medicines for cancer chemo-
therapy, Tiwari and colleagues investigated the effective-
ness of the combination of drugs operating synergistically. 
They have studied the effect of Graphene oxide polyvi-
nylpyrrolidone- quercetin -gefitinib (GO-PVP-QSR-GEF) 
on the ovarian cancer cells (PA-1). They illustrated that 
quercetin could has a synergic effect on gefitinib anti-
cancer property on PA-1 cells, an ovarian cancer origi-
nated cell line [98]. In addition, it revealed that quercetin 
decreased the cell viability of PA-1 cells in a dose and 
time-dependent procedure. It is worth noticing that 
they reported 75  μM of quercetin as optimal dose. The 
molecular mechanism evaluation following the promot-
ing apoptotic effect of quercetin in PA-1 cell showed that 
quercetin regulates the intrinsic apoptotic pathway that 
lead to reducing of the anti-apoptotic molecules such as 
Bcl-2, Bcl-xL while increased the expression level of pro-
apoptotic molecules such as caspase-3, caspase-9, cyto-c, 
Bid, Bad, and Bax [99]. Doxorubicin is a chemotherapeu-
tic agent that used in various cancer including ovarian, 
thyroid, breast, and lung cancer but a notable unfavora-
ble effect such as cardiotoxicity limits its use [100]. To 
overcome this limit, scientific used quercetin as a che-
mosensitizer in combination with doxorubicin. Survey in 
ovarian cancer xenograft model indicated that quercetin 
is able to attenuate the doxorubicin-induced cardiotox-
icity. Ren et al. investigated the function of quercetin on 
the proliferation and apoptosis of ovarian cancer cell line 
SKOV-3 in order to present an experimental foundation 
for the clinical utilization of quercetin in the therapy of 
ovarian cancer. Quercetin repressed the proliferation of 
ovarian cancer SKOV-3 cells in a time- and dose-depend-
ent manner. Also, quercetin could promote the apopto-
sis of SKOV-3 cells and decreased the survivin protein 
expression. Flow cytometry report revealed that querce-
tin provoked SKOV-3 cells cycle arrest in the G0/G1 and 
a notable reduction in the rate of cells at the G2/M phase; 
moreover, the apoptosis percentage was recognized to 
boost resulting quercetin therapy [101].
Current evidences about quercetin effects on enhanc-
ing the sensitivity of tumor radiotherapy have revealed 
that quercetin could enhance the effect of radiation-
induced cell death. The combination quercetin treatment 
with X-irradiation increased the DNA damages and cre-
ated common apoptotic cell death; as well resulted in 
increasing of Bax level and decreasing of Bcl-2 level in 
ovarian cancer cell lines (OV2008 and SKOV3) compared 
to cells presented to quercetin or X-rays alone. In addi-
tion, a combination of quercetin treatment with radiation 
remarkably suppressed the growth of tumors, followed 
by the induction of p53, CCAAT/enhancer-binding pro-
tein homologous protein (CHOP) that is the ER stress 
biomarker, and γ-H2AX. Conclusively, these outcomes 
showed that quercetin served as a hopeful radiosensitizer 
by p53-dependent ER stress signals in human ovarian 
tumor xenograft model [102].
Quercetin can result in stimulate the ER stress path-
way that lead to the cause of cell death and apoptosis 
[103–105]. Quercetin provoked the ER stress by directly 
provoking apoptosis via raised levels of GRP78, CHOP 
that both of them are markers of ER stress and cleaved 
caspase 4 that has been recognized as a principal per-
former in ER-induced apoptosis in ovarian cancer cell 
lines and primary ovarian cancer cells [20, 106]. In order 
to explore the mechanism of quercetin-induced ER 
stress and apoptosis, some researchers have focused on 
the p-STAT3/Bcl-2 axis, which was verified to be able 
to modulate caspase-cleavage to reduce apoptosis. The 
outcomes determined that quercetin-induced ER stress 
is associated with the mitochondrial apoptosis pathway 
via activation of the p-STAT3/Bcl-2 axis. Unexpectedly, 
the repression of ER stress could not repeal quercetin-
induced apoptosis. Additional functional investigations 
exhibited that quercetin-induced ER stress could stimu-
late protective autophagy simultaneously by arousing the 
p-STAT3/Bcl-2 axis in this manner. Furthermore, 3-MA, 
an autophagy scavenger, was presented to improve 
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quercetin’s anticancer influences in an ovarian cancer 
mice xenograft model. Ultimately, this study introduced 
a unique function of ER stress as a “double edge sword” 
engaging in quercetin-induced apoptosis in ovarian can-
cer and might present a new viewpoint to recognize in 
clinical investigations of biological modifiers that may 
evade drug resistance in subjects through targeting pro-
tective autophagy pathways [20].
Quercetin, because of its little absorption in gastroin-
testinal tract, enormous first pass metabolism, gastroin-
testinal instability, low hydrophilicity, and poor solubility, 
is a challenging pharmacological agent to be delivered 
[107]. Its oral bioavailability has been illustrated to be less 
than 17% in animals and less than 2% in human, hence 
restricting its clinical use utilizing conventional dosage 
forms [108, 109]. Therefore, an ameliorated quercetin 
oral formulation is needed with higher efficacy and better 
bioavailability.
Nanoformulation-based approaches for potential ther-
apeutic molecules delivery have been shown to amelio-
rate the efficiency of such molecules, which otherwise 
suffer from particular restrictions [110–112]. Various 
delivery systems have been demonstrated for querce-
tin, including microemulsion, nanoparticles, liposomes, 
and solid lipid nanoparticles for different applications, 
including in aging and neurodegenerative disease [109, 
113–115].
Hydrophobic drugs that are encapsulated into nano-
particles become completely dispersible in water and 
injectable intravenously. Anticancer drugs which are 
delivered by biodegradable polymeric nanoparticles, as 
great candidates for anticancer drug delivery systems 
[116], are currently used in clinical practice. Poly(3-
caprolactone)/poly(ethylene glycol)(PCL/PEG) block 
copolymers are easy to produce, amphiphilic and biode-
gradable, indicating hopeful application in drug delivery 
systems [117]. Recently, utilizing the PCL/PEG nano-
particles for encapsulating drugs to ameliorate the water 
solubility of hydrophobic drugs has attracted attentions. 
Gao and colleagues evaluated quercetin nanoformulation 
effects on the colony formation ability and proliferation 
of ovarian cells [95]. Encapsulated quercetin into biode-
gradable monomethoxy poly (ethylene glycol)-poly(ε-
caprolactone) (MPEG-PCL) micelles and attempted to 
yield proof-of-principle for the treatment of ovarian can-
cer with this quercetin nano-formulation. These querce-
tin loaded MPEG-PCL (QU/MPEG-PCL) micelles with 
drug loading of 6.9% had a mean particle size of 36 nm, 
providing the complete quercetin dispersion in water.
The growth of A2780S ovarian cancer cells was 
suppressed in  vitro by quercetin on a concentra-
tion-dependent approach. In addition, intravenously 
administered QU/MPEG-PCL micelles remarkably 
inhibited the xenograft A2780S ovarian tumors growth 
in vivo by suppressing angiogenesis and inducing apop-
tosis of cancer cells, which is correlated with caspase-3 
and -9 activation. In addition, alteration of mitochondrial 
trans-membrane potential, downregulation of Bcl-2 and 
MCL-1, and upregulation of Bax were seen, indicating 
that apoptosis induction effects is via the mitochondrial 
apoptotic pathways. Anti-proliferative effect of quercetin 
against A2780S cells was through decreasing phosphoryl-
ated Akt as well as phosphorylated p44/42 mitogen-acti-
vated protein kinase. Therefore, QU/MPEG-PCL micelles 
were shown to be novel quercetin nano-formulations 
with a beneficial application in the treatment of ovarian 
cancer [95].
In order to show the susceptibility of cisplatin-resistant 
ovarian cancer cells to quercetin and anticancer proper-
ties of this compound, Long et al. conducted in vivo and 
in  vitro studies on the impact of PEGylated liposomal 
quercetin (Lipo-Que) on cisplatin-resistant (A2780cp) 
and cisplatin-sensitive (A2780s) human ovarian can-
cer models [118]. The findings revealed that Lipo-Que 
induced cell cycle arrest as well as apoptosis, and sup-
pressed cell proliferation in both A2780cp and A2780s 
cells in  vitro. Additionally, anticancer feature of Lipo-
Que was assessed in both cisplatin-resistant and cispl-
atin-sensitive human ovarian tumor xenograft models in 
nude mice. Compared to normal saline, blank liposomes 
and free quercetin, Lipo-Que considerably inhibited 
tumor growth in both models. Moreover, immunofluo-
rescence and immunohistochemistry methods demon-
strated that Lipo-Que suppressed tumors proliferation, 
reduced microvessel density, and induced apoptosis in 
both A2780cp and A2780s tumor models. Thus, Lipo-
Que was proposed to be an efficient formulation for 
tumor growth inhibition in both cisplatin-resistant and 
cisplatin-sensitive human ovarian cancers [118].
Teekaraman and his colleagues conducted an in  vitro 
study and illustrated that quercetin, at dose of 50 and 
75 μM, is able to induce apoptosis in metastatic ovarian 
cancer cells leading to inhibit their growth [99]. On the 
other hand, it was recently reported that co-treatment 
with quercetin and selenium have synergistic radiopro-
tective and cytoprotective impacts on oxidative stress in 
endometrial adenocarcinoma cells [119]. Table 2 summa-
rized various studies quercetin in ovarian cancer.
Conclusion
It is widely accepted that ovarian cancer is the main cause 
of deaths associated with gynecology cancer across the 
world. Utilizing compounds derived from plants has 
been extensively considered for the treatment of can-
cer. According to the obtained evidences, quercetin can 
prevent ovarian cancer through a couple of mechanisms 
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including anti-inflammation, pro-oxidation, anti-prolifer-
ation, and cell cycle arrest. Moreover, this natural com-
pound is capable of strengthening the impacts of other 
chemotherapeutic medications. Further studies should 
also perform to illustrate its detailed mechanisms of 
action regarding ovarian cancer. Besides various advan-
tages, utilization of quercetin is associated with differ-
ent limitations such as very poor bioavailability, poor 
absorption, rapid metabolism, chemical instability, and 
rapid systemic elimination. Utilization of quercetin ana-
logs and targeting quercetin by nanotechnology-based 
approaches may therefore overcome these limitations. 
Hence, it seems that these platforms can potentially open 
new horizons in the utilization of quercetin as power-
ful therapeutic agent alone or in combination with other 
drugs in the treatment of different types of cancer such as 
ovarian cancer. So far, there have not been clinical studies 
to assess the anti-ovarian cancer effects of quercetin. It 
seems that clinical studies will help us to assess the safety 
and potency of this drug for the treatment of ovarian 
cancer.
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